Sio Gene Therapies (SIOX) Stock Analysis

What Sio Gene Therapies does

Sio Gene Therapies Inc. is a biotechnology company in the clinical development phase, committed to pioneering gene therapies designed to fundamentally alter the prognosis for patients afflicted with neurodegenerative conditions. Its therapeutic pipeline is supported by strategic licensing agreements, including one with Oxford BioMedica (UK) Ltd. for the advancement and market introduction of AXO-Lenti-PD and associated gene therapy offerings. Furthermore, Sio Gene Therapies collaborates with The University of Massachusetts Medical School on the development and commercialization of other gene therapy candidates, notably AXO-AAV-GM1 and AXO-AAV-GM. Incorporated in 2014 and headquartered in New York, New York, the entity was known as Axovant Gene Therapies Ltd. prior to its renaming in November 2020.

Key metrics

ETFs linked to SIOX

Broad-market and Healthcare sector ETFs an investor holding Sio Gene Therapies is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SIOX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Sio Gene Therapies?

Sio Gene Therapies trades under the ticker SIOX on NASDAQ.

Which exchange is SIOX listed on?

SIOX is listed on NASDAQ.

What sector does Sio Gene Therapies operate in?

Sio Gene Therapies is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SIOX in a portfolio?

PortView shows SIOX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.